Next Generation Gene Editing and Genomic Engineering Tools Innovations and Therapeutic Applications

The decoding of the human genome and the subsequent realization that genetic variation underlies both physiological diversity and pathological states have fundamentally reshaped the landscape of modern biological and medical sciences. Genomic engineering, defined as the deliberate and targeted modification of genetic material within living cells, has emerged as a transformative discipline enabling precise manipulation of DNA sequences to study gene function, model disease mechanisms, and develop novel therapeutic interventions. Over the past several decades, advances in molecular biology, sequencing technologies, and computational analysis have converged to create unprecedented opportunities for engineering genomes with increasing precision and functional relevance (1). The importance of genomic engineering extends across nearly every domain of biotechnology and medicine. In basic research, it provides powerful tools to interrogate gene regulatory networks, elucidate developmental pathways, and uncover molecular determinants of cellular identity. In translational science, genome editing has enabled the development of disease models that faithfully recapitulate human genetic disorders, thereby accelerating drug discovery and target validation. In clinical medicine, the prospect of correcting disease-causing mutations at their source has shifted therapeutic paradigms from symptomatic management toward potentially curative genetic interventions (2). Despite this promise, early approaches to gene manipulation were characterized by substantial technical and biological limitations. Classical methods such as random mutagenesis, homologous recombination, and transgenic overexpression lacked efficiency and control, often requiring extensive screening and selection to identify desired genetic modifications. These approaches were time consuming, costly, and frequently associated with unpredictable genomic integration events that complicated data interpretation and raised safety concerns (3). The development of programmable nuclease-based technologies marked a critical turning point in the evolution of genomic engineering. Zinc finger nucleases and transcription activator like effector nucleases introduced the concept of site-specific DNA cleavage, enabling targeted genome modification through endogenous DNA repair pathways. While these tools represented a significant advance over earlier methods, their widespread adoption was hindered by complex protein engineering requirements, limited scalability, and variable editing efficiencies (4,5). The advent of CRISPR Cas systems fundamentally altered the trajectory of genome editing by introducing a simple, RNA guided mechanism for precise DNA targeting. Originally identified as an adaptive immune system in prokaryotes, CRISPR Cas technology was rapidly repurposed into a versatile genome editing platform capable of inducing targeted double strand breaks at virtually any genomic locus. The simplicity of guide RNA design, combined with high editing efficiency and adaptability across diverse organisms, established CRISPR Cas as the dominant genome editing technology within a decade of its introduction (6,7). However, the reliance of early CRISPR based approaches on double strand DNA breaks raised concerns regarding genomic stability, off target mutagenesis, and activation of DNA damage responses. These limitations motivated the development of next generation editing tools designed to achieve greater precision while minimizing unintended genomic alterations. Base editing technologies emerged as a breakthrough by enabling direct conversion of specific nucleotides without inducing double strand breaks or requiring donor DNA templates. Cytosine and adenine base editors expanded the editing repertoire to include precise single nucleotide modifications, addressing a substantial fraction of known pathogenic point mutations (8,9). Prime editing further extended the capabilities of genome engineering by introducing a search and replace mechanism capable of installing all possible base substitutions as well as small insertions and deletions with high specificity. By integrating a reverse transcriptase with a modified CRISPR Cas system, prime editing offers a flexible and programmable platform for precise genome modification, overcoming many of the constraints associated with earlier editing strategies (10). Beyond direct sequence modification, the expansion of CRISPR based technologies into epigenome editing and transcriptional regulation has opened new avenues for modulating gene expression without altering the underlying DNA sequence. These approaches leverage catalytically inactive Cas proteins fused to regulatory domains to activate, repress, or remodel chromatin, enabling reversible and context dependent control of gene function. Such tools have proven invaluable for functional genomics, disease modeling, and the study of complex regulatory landscapes (11). The translation of next generation gene editing technologies into therapeutic applications has accelerated rapidly, with multiple clinical trials demonstrating promising outcomes in the treatment of genetic disorders, hematological diseases, and cancer. Notably, the approval of CRISPR based therapies for inherited blood disorders represents a historic milestone, validating the clinical feasibility of genome editing based interventions (4,10). Concurrently, advances in delivery strategies, including viral vectors, lipid nanoparticles, and cell based platforms, have addressed key barriers to in vivo and ex vivo application of gene editing systems (12). Despite these advances, significant challenges remain. Off target effects, immune responses to editing components, mosaicism, and long-term safety concerns continue to shape the risk benefit assessment of gene editing therapies. Ethical considerations surrounding germline editing, equitable access to genomic medicine, and responsible governance of powerful biotechnologies further underscore the need for robust regulatory frameworks and international consensus (13). This review aims to provide a comprehensive and integrative overview of next generation gene editing and genomic engineering technologies, tracing their evolution from early nuclease-based systems to advanced precision editing platforms. By examining the molecular mechanisms, technological innovations, delivery strategies, and therapeutic applications of these tools, this article highlights both the transformative potential and the critical challenges shaping the future of genomic engineering in science and medicine (14).

2. Evolution of Gene Editing Technologies

The evolution of gene editing technologies reflects a progressive refinement of molecular tools designed to manipulate genetic material with increasing accuracy, efficiency, and biological safety. Early efforts in genomic engineering relied heavily on random integration methods and homologous recombination, which were limited by low targeting efficiency and unpredictable genetic outcomes. These approaches, although instrumental in advancing molecular genetics, were poorly suited for precise genome manipulation and clinical translation due to extensive off target effects and labor intensive workflows (15,16). The first generation of targeted genome editing tools emerged with the development of engineered nucleases, particularly zinc finger nucleases. Zinc finger nucleases are synthetic proteins composed of a DNA binding domain derived from zinc finger motifs fused to the FokI endonuclease catalytic domain. Each zinc finger recognizes a specific triplet of nucleotides, and multiple zinc fingers are assembled to target a desired DNA sequence. When two zinc finger nuclease monomers bind adjacent DNA sequences, the FokI domains dimerize and introduce a site specific double strand break, which is subsequently repaired by cellular DNA repair pathways such as non homologous end joining or homology directed repair (17). While zinc finger nucleases demonstrated the feasibility of programmable genome editing, their practical implementation was constrained by several limitations. The design and assembly of zinc finger arrays required extensive expertise, and the context dependent interactions between zinc finger domains often resulted in unpredictable binding specificity. Furthermore, off target cleavage events and cytotoxicity associated with double strand breaks limited their broader application, particularly in therapeutic settings (18). Transcription activator like effector nucleases represented a significant advancement over zinc finger nucleases by simplifying DNA recognition. These nucleases are based on transcription activator like effector proteins derived from Xanthomonas bacteria, which contain repetitive DNA binding modules capable of recognizing single nucleotides through a simple amino acid code. By linking these modules to the FokI nuclease domain, transcription activator like effector nucleases enabled more predictable and flexible targeting of genomic sequences (19). Despite their improved specificity, transcription activator like effector nucleases remained limited by large protein size, complex cloning procedures, and challenges in delivery to target cells. The requirement for protein engineering for each new target site also restricted scalability, making high throughput genome editing difficult to achieve. Nevertheless, these tools were successfully applied in several preclinical and clinical contexts, including the treatment of hematological disorders and the generation of genetically modified organisms (20). The transition from protein guided to RNA guided genome editing marked a defining milestone in the evolution of genomic engineering. The discovery and adaptation of CRISPR Cas systems provided a fundamentally different mechanism for sequence recognition and cleavage. Unlike zinc finger nucleases and transcription activator like effector nucleases, CRISPR based systems rely on a short guide RNA to direct a Cas nuclease to a complementary DNA sequence, eliminating the need for complex protein engineering. This innovation dramatically reduced the technical barrier to genome editing and enabled rapid, cost effective, and scalable genetic manipulation across a wide range of organisms (21). Early studies demonstrated that CRISPR Cas9 could achieve editing efficiencies comparable to or exceeding those of first generation nucleases, while offering unparalleled ease of design and multiplexing capabilities. Multiple guide RNAs could be introduced simultaneously to target several genomic loci, facilitating complex genetic modifications that were previously impractical. These attributes led to the rapid adoption of CRISPR Cas systems as the dominant platform for genome editing in research and biotechnology. However, the initial CRISPR Cas9 systems retained dependence on double strand DNA breaks, thereby inheriting some of the limitations observed with earlier nuclease-based technologies. Variable repair outcomes, insertion and deletion mutations, chromosomal rearrangements, and off target cleavage raised concerns regarding genomic integrity and therapeutic safety (22). These challenges catalyzed further innovation, driving the development of next generation editing strategies that build upon the CRISPR framework while minimizing DNA damage. The evolution of gene editing technologies thus reflects a continuum from inefficient and nonspecific approaches toward highly programmable and precise systems. Each generation of tools has addressed critical limitations of its predecessors, culminating in advanced CRISPR based platforms that enable not only targeted DNA cleavage but also precise nucleotide modification, transcriptional regulation, and epigenetic control. This evolutionary trajectory has laid the foundation for the next era of genomic engineering, characterized by precision medicine, personalized therapies, and responsible innovation (23,24).

Figure 1. Timeline illustrating the evolution of gene editing technologies from homologous recombination to zinc finger nucleases, transcription activator like effector nucleases, and CRISPR based systems.

3. CRISPR Cas Systems the Foundation Of Next Generation Editing

The emergence of CRISPR Cas systems represents the most significant breakthrough in the history of genomic engineering, fundamentally redefining the precision, scalability, and accessibility of gene editing technologies. Derived from an adaptive immune defense mechanism in bacteria and archaea, CRISPR Cas systems function by recognizing and cleaving foreign nucleic acids in a sequence specific manner guided by RNA molecules. The translation of this naturally occurring system into a programmable genome editing platform has transformed both basic biological research and translational medicine (25,26). At the core of CRISPR mediated genome editing lies the Cas9 nuclease, a class two CRISPR effector protein that introduces site specific double strand breaks in DNA. The targeting specificity of Cas9 is dictated by a single guide RNA, which contains a sequence complementary to the target DNA and directs the Cas9 protein to the desired genomic locus. Upon recognition of a protospacer adjacent motif sequence, Cas9 undergoes a conformational change that enables cleavage of both DNA strands, activating endogenous DNA repair pathways such as non-homologous end joining or homology directed repair. This mechanism enables targeted gene disruption, insertion, or replacement with high efficiency across diverse cell types and organisms (27). Despite its versatility, early CRISPR Cas9 systems exhibited limitations related to off target activity and imprecise repair outcomes. Off target cleavage events, arising from partial guide RNA mismatches, posed risks of unintended genomic alterations that could compromise cellular function and therapeutic safety. In response to these challenges, extensive efforts were directed toward engineering high fidelity Cas9 variants with improved specificity. Modified Cas9 proteins such as SpCas9 HF1, eSpCas9, HypaCas9, and Sniper Cas9 were developed by altering residues involved in DNA binding, thereby reducing nonspecific interactions and minimizing off target effects while maintaining robust on target activity (28). Beyond Cas9, the discovery and characterization of alternative Cas enzymes have expanded the functional landscape of CRISPR based genome editing. Cas12, formerly known as Cpf1, introduced several mechanistic advantages over Cas9, including the generation of staggered DNA cuts, recognition of distinct protospacer adjacent motif sequences, and reduced protein size that facilitates delivery. Cas12 mediated editing has demonstrated improved targeting flexibility and lower off target activity in certain genomic contexts, making it particularly attractive for therapeutic applications requiring compact delivery vectors (29). The diversification of CRISPR technologies further accelerated with the identification of Cas13 enzymes, which uniquely target RNA rather than DNA. Cas13 systems enable programmable cleavage of single stranded RNA, allowing transient and reversible modulation of gene expression without permanent genomic alteration. This capability has opened new avenues for transcriptome engineering, antiviral strategies, and diagnostic applications. Cas13 variants such as Cas13a, Cas13b, and Cas13d have demonstrated high efficiency and specificity in targeting viral RNA and disease associated transcripts, offering therapeutic potential for conditions driven by aberrant RNA expression (30). In parallel, advances in protein engineering and structural biology have enabled the rational design of Cas enzymes with enhanced performance characteristics. Compact Cas variants and metagenome derived orthologs have been developed to overcome size constraints associated with viral delivery systems such as adeno associated viruses. These innovations have significantly expanded the feasibility of in vivo genome editing by enabling efficient packaging and tissue specific delivery of CRISPR components (31). Improvements in CRISPR specificity have also been achieved through optimization of guide RNA design and delivery modalities. Chemical modification of guide RNAs, truncated guide sequences, and computational algorithms for predicting off target sites have collectively contributed to improved editing accuracy. Furthermore, delivery of CRISPR components as ribonucleoprotein complexes has reduced prolonged nuclease activity, thereby limiting off target effects and enhancing safety profiles for therapeutic applications (32). The versatility of CRISPR Cas systems extends beyond genome editing to encompass transcriptional regulation, epigenetic modulation, and molecular diagnostics. Catalytically inactive Cas proteins, known as dead Cas, have been repurposed as programmable DNA binding platforms for gene activation, repression, and chromatin remodeling when fused to regulatory domains. These adaptations have transformed CRISPR from a simple genome cutting tool into a multifunctional platform for precise control of cellular function (33). Collectively, CRISPR Cas systems constitute the foundation of next generation gene editing technologies, providing a modular and adaptable framework upon which advanced precision editing tools such as base editing and prime editing have been built. The continuous refinement of Cas enzymes, guide RNA architectures, and delivery strategies underscores the dynamic evolution of CRISPR based technologies and their central role in shaping the future of genomic engineering and therapeutic innovation (34).

Figure 2. Molecular mechanism of CRISPR Cas9 mediated genome editing illustrating guide RNA binding, protospacer adjacent motif recognition, DNA cleavage, and cellular repair pathways.

lowchart illustrates the stepwise workflow of CRISPR-Cas–based genome editing. The process begins with target gene selection followed by the design of a specific guide RNA complementary to the target DNA sequence. The guide RNA is assembled with the Cas9 nuclease to form the CRISPR-Cas complex, which is then delivered into target cells. Upon recognition of the protospacer adjacent motif (PAM), Cas9 induces a site-specific double-strand break in the DNA. The resulting break is repaired by cellular DNA repair pathways, either non-homologous end joining (NHEJ), leading to insertions or deletions and gene disruption, or homology-directed repair (HDR), enabling precise genetic modification.

4. Base Editing Technologies

Base editing technologies represent a major conceptual and technical advancement in genomic engineering by enabling precise nucleotide substitutions without the induction of double strand DNA breaks. Unlike conventional CRISPR Cas mediated editing, which relies on error prone DNA repair pathways, base editors directly convert one nucleotide into another at a targeted genomic locus through chemical modification of DNA bases. This approach significantly reduces the risk of insertions deletions chromosomal rearrangements and p53 mediated cellular stress responses, thereby improving editing predictability and safety for therapeutic applications (35,36). The fundamental architecture of base editors consists of a catalytically impaired Cas nuclease, typically a nickase or inactive Cas9, fused to a nucleotide deaminase enzyme and guided by a single guide RNA. Upon binding to the target DNA sequence, the Cas protein unwinds a short region of the DNA duplex, exposing a single stranded DNA loop that serves as a substrate for the deaminase. The deaminase catalyzes the chemical conversion of a specific nucleotide within a defined editing window, which is subsequently resolved into a permanent base substitution through DNA replication or repair mechanisms (37). Cytosine base editors were the first class of base editors to be developed and are designed to convert cytosine into thymine. These editors typically employ cytidine deaminases such as APOBEC1 or engineered variants that catalyze the deamination of cytosine to uracil. During DNA replication or repair, uracil is recognized as thymine, resulting in a C to T transition. Early cytosine base editors achieved high editing efficiencies but exhibited off target activity and undesired by products, prompting extensive optimization of deaminase domains and Cas protein variants to improve fidelity (38). Adenine base editors expanded the scope of base editing by enabling the conversion of adenine to guanine, a transformation previously considered infeasible due to the lack of naturally occurring DNA adenine deaminases. This challenge was overcome through protein engineering and directed evolution of the bacterial TadA enzyme, resulting in adenine base editors capable of efficient A to G conversions. Adenine base editors have demonstrated superior specificity and lower off target activity compared to early cytosine base editors, making them particularly attractive for therapeutic genome editing (39). Recent innovations have focused on improving editing efficiency expanding target scope and minimizing unintended DNA and RNA modifications. Structure guided engineering has produced compact and high fidelity base editors with reduced RNA off target activity while retaining robust on target performance. The development of near PAMless base editors and Cas12 derived base editors has further expanded the range of editable genomic loci, overcoming limitations imposed by protospacer adjacent motif requirements (40). Base editing has demonstrated significant biomedical relevance due to its ability to correct pathogenic point mutations that underlie a large proportion of inherited genetic diseases. Preclinical studies have shown successful correction of disease causing mutations in animal models of metabolic neurological and cardiovascular disorders. In vivo delivery of base editors using viral vectors has achieved therapeutically meaningful editing efficiencies in tissues such as liver brain retina and muscle, highlighting the translational potential of this technology (41). Despite these advances, base editing technologies are not without limitations. Transcriptome wide RNA editing and Cas independent DNA deamination have been reported for certain editor configurations, underscoring the need for rigorous safety evaluation and continued optimization. Ongoing research efforts aim to engineer next generation base editors with enhanced precision reduced immunogenicity and improved compatibility with clinical delivery platforms (42). Overall, base editing technologies represent a transformative step toward precision genomic medicine, offering a powerful alternative to double strand break based genome editing. Their continued refinement is expected to play a central role in the treatment of monogenic diseases functional genomics studies and the development of safer and more predictable gene therapies (43)

Figure 3. Schematic representation of base editing mechanism illustrating Cas nickase binding guide RNA targeting deaminase mediated nucleotide conversion and fixation of base substitution.

Table 1. Comparison of Cytosine Base Editors (CBEs) and Adenine Base Editors (ABEs)

5. Prime Editing A New Precision Tool

Prime editing represents a transformative advancement in genome engineering, extending the capabilities of traditional CRISPR Cas systems and base editing by enabling highly precise DNA modifications without requiring double strand breaks or donor DNA templates. This technology addresses limitations associated with conventional CRISPR Cas9 systems, including off target mutations and imprecise repair outcomes, thereby offering enhanced safety and versatility for therapeutic applications (44). Prime editing employs a fusion of a Cas9 nickase and an engineered reverse transcriptase, guided by a prime editing guide RNA (pegRNA), which simultaneously specifies the target genomic locus and encodes the desired nucleotide modification. The Cas9 nickase introduces a single stranded nick at the target site, and the reverse transcriptase utilizes the pegRNA as a template to synthesize the edited DNA sequence directly onto the genome, resulting in precise base substitutions, insertions, or deletions (45).Unlike base editing, which is limited to specific transition mutations, prime editing offers the capability to generate all twelve possible base-to-base substitutions as well as small insertions and deletions, thereby substantially expanding the scope of editable genetic variations. This increased flexibility makes prime editing particularly suitable for correcting pathogenic mutations associated with a wide range of monogenic diseases, including metabolic, cardiovascular, neurological, and ocular disorders (46). Furthermore, prime editing reduces reliance on cellular DNA repair mechanisms that are error prone, thus minimizing undesired indels and chromosomal rearrangements commonly observed in conventional CRISPR Cas9 mediated editing (47). Recent studies have demonstrated the efficacy of prime editing in both mammalian and plant cells, achieving high editing efficiency with reduced off target effects. Innovations in pegRNA design, reverse transcriptase engineering, and delivery modalities, including adeno associated viral vectors and lipid nanoparticles, have significantly enhanced the efficiency, specificity, and therapeutic potential of this technology (48). Prime editing has also been combined with additional Cas variants to expand target site accessibility, reduce protospacer adjacent motif constraints, and improve editing precision in diverse cell types (49). Despite its promise, prime editing faces challenges related to delivery efficiency, cellular uptake, and potential immune responses against the editing components. Strategies to optimize tissue specific delivery and reduce immunogenicity are under active investigation, with the goal of enabling safe and effective in vivo therapeutic applications (50). In preclinical models, prime editing has successfully corrected disease causing mutations, demonstrating substantial functional improvement without inducing significant off target alterations, underscoring its potential as a next generation tool for precision genome engineering (51). Overall, prime editing represents a significant evolution in genome editing technologies, offering unprecedented versatility, accuracy, and safety. Its ability to precisely rewrite genomic sequences without inducing double strand breaks positions it as a central technology for future therapeutic interventions and personalized genomic medicine, bridging the gap between experimental research and clinical application (52).

Figure 4. Schematic of prime editing mechanism illustrating Cas9 nickase and reverse transcriptase fusion guided by pegRNA, showing target site recognition, DNA nicking, reverse transcription, and integration of the desired edit.

6. Epigenome Editing and Transcriptional Control

Epigenome editing has emerged as a pivotal extension of genome engineering, providing the ability to manipulate gene expression and chromatin structure without altering the underlying DNA sequence. Unlike conventional genome editing, which directly modifies nucleotide sequences, epigenome editing leverages catalytically inactive Cas proteins (dCas) fused to transcriptional activators, repressors, or chromatin-modifying enzymes to achieve locus-specific regulation of gene expression (53). This approach allows for precise and reversible modulation of epigenetic marks, such as DNA methylation and histone modifications, enabling the study of causal relationships between epigenetic states and cellular phenotypes (54). CRISPR-based epigenome editors utilize guide RNAs to direct dCas proteins to specific genomic loci, where attached effector domains perform targeted epigenetic modifications. For instance, dCas9 fused with histone acetyltransferases can promote transcriptional activation by acetylating histone tails, whereas fusion with DNA methyltransferases can suppress gene expression by inducing site-specific methylation (55). Such precise control has been employed to investigate complex regulatory networks, elucidate functional genomics, and develop disease models. The technology has demonstrated significant therapeutic potential, including reactivation of silenced tumor suppressor genes, suppression of oncogenes, and modulation of metabolic pathways implicated in diabetes and obesity (56). Recent innovations have expanded the versatility of epigenome editing. Multi-effector systems now allow simultaneous activation and repression of multiple genes, while inducible systems provide temporal control over gene expression (57). Advances in delivery strategies, such as lipid nanoparticles, viral vectors, and ribonucleoprotein complexes, have enhanced cellular uptake, reduced off-target effects, and enabled in vivo applications (58). Studies in neuronal systems have shown that epigenome editing can modulate specific neural circuits, influencing behavior and disease phenotypes, highlighting its potential for neurotherapeutic interventions (59). Despite these advances, challenges remain, including incomplete understanding of epigenetic crosstalk, context-dependent effects, and potential immunogenicity of CRISPR components (60). Optimization of effector domain specificity, improved delivery methods, and rigorous safety evaluations are essential for translating epigenome editing into clinical therapies (2,3,14). Future directions involve integrating artificial intelligence for predictive targeting, developing RNA-guided epigenetic editors, and combining epigenome editing with base and prime editing to achieve multi-layered genomic regulation (61). Overall, CRISPR-based epigenome editing represents a transformative tool for precise and programmable regulation of gene expression. By enabling targeted, reversible, and multiplexable modulation of the epigenetic landscape, it offers unprecedented opportunities for disease modeling, functional genomics, and therapeutic intervention across diverse biological systems (62).

Figure 5. Schematic of CRISPR-dCas9 based epigenome editing showing targeting of dCas9-effector fusions to genomic loci to modulate histone acetylation, methylation, and DNA methylation for transcriptional activation or repression.

7. Delivery Strategies for Gene Editing Systems

Efficient and precise delivery of gene editing tools into target cells is a fundamental challenge in translating genomic engineering technologies into therapeutic applications. The success of CRISPR-Cas systems, base editors, and prime editors heavily relies on their ability to reach specific tissues, enter target cells, and achieve sufficient intracellular activity while minimizing off-target effects and immunogenicity (63). Delivery strategies are broadly categorized into viral and non-viral approaches, each with distinct advantages and limitations, and ongoing innovations continue to expand the scope and safety of gene editing therapies.

Viral Delivery Methods

Viral vectors have long been used as delivery vehicles due to their natural capacity for efficient cellular entry and gene expression. Adeno-associated viruses (AAVs) are widely employed in in vivo applications owing to their low immunogenicity and ability to transduce dividing and non-dividing cells. However, AAV vectors are constrained by limited cargo capacity, which poses challenges for delivering larger constructs such as Cas9 fused with base editors or prime editors (64). Lentiviral vectors offer a larger payload and stable genomic integration, making them suitable for ex vivo gene editing of hematopoietic stem cells and T lymphocytes. Despite their utility, integration raises concerns regarding insertional mutagenesis, emphasizing the need for careful vector design and genomic targeting (65).

Non-Viral Delivery Methods

Non-viral strategies provide alternatives that reduce the risks associated with viral integration and immune responses. Lipid nanoparticles (LNPs) have gained prominence due to their capacity to encapsulate RNA or protein components of gene editors and deliver them systemically or locally with high efficiency. Recent innovations include tissue-specific LNPs engineered for liver, lung, and central nervous system targeting, improving therapeutic index and reducing off-target biodistribution (66). Electroporation and nucleofection are widely applied ex vivo to facilitate direct delivery of ribonucleoprotein complexes into primary cells, achieving transient expression that minimizes prolonged exposure and associated off-target effects (67).

Nanoparticle-Based and Hybrid Systems

Emerging nanoparticle-based delivery systems integrate features of both viral and non-viral methods. Polymer-based nanoparticles, gold nanoparticles, and hybrid lipid-polymer carriers offer tunable release profiles, biocompatibility, and the potential for targeted delivery via surface ligands (68). These systems enable sequential delivery of multiple editing components, a crucial requirement for prime editing or multiplexed CRISPR interventions, where coordinated temporal expression is necessary for optimal editing efficiency.

8. Challenges and Innovations in Delivery

Despite progress, significant challenges remain. Physical barriers such as extracellular matrix, tissue-specific uptake, and endosomal escape limit intracellular availability of editing components. Immune recognition of Cas proteins and nucleic acids can trigger clearance or inflammatory responses, particularly in systemic administration (69). To overcome these limitations, advanced strategies combining biodegradable nanoparticles, cell-penetrating peptides, and stimuli-responsive carriers are being developed. Additionally, ex vivo editing of patient-derived cells followed by transplantation remains a preferred approach for hematological and immune disorders, allowing precise control and safety validation prior to clinical use (70). Efficient delivery of next-generation gene editing systems remains a critical determinant of therapeutic success. While viral vectors continue to dominate clinical translation due to their established safety and efficacy, non-viral and nanoparticle-based approaches are rapidly advancing, offering customizable, tissue-specific, and transient editing solutions. Integration of multi-component delivery strategies, optimization of endosomal escape, and immune evasion techniques are expected to accelerate clinical adoption and expand the repertoire of diseases amenable to gene editing therapies (71).

9. Therapeutic Applications of Next-Generation Gene Editing

The advent of next-generation gene editing technologies, particularly CRISPR-Cas systems, base editors, and prime editors, has fundamentally transformed the therapeutic landscape for genetic disorders, cancer, infectious diseases, and regenerative medicine. Unlike conventional gene therapy approaches, which often rely on gene addition or random integration, these tools allow precise, efficient, and targeted manipulation of genomic sequences, thereby correcting pathogenic mutations at their origin with unprecedented accuracy (72). In the context of genetic disorders, CRISPR-Cas9 has demonstrated remarkable efficacy in correcting monogenic diseases. For example, hematopoietic stem cell editing has been successfully applied in sickle cell disease, β-thalassemia, and other blood disorders by either disrupting the mutant gene or reactivating compensatory fetal haemoglobin expression. Base editors and prime editors have further refined these interventions, enabling the correction of single-nucleotide mutations without introducing double-strand breaks, reducing off-target effects and cellular stress. Clinical translation of these tools has already led to FDA-approved therapies such as Casgevy for sickle cell disease, exemplifying their therapeutic promise (73). In cancer therapy, next-generation editing technologies are being harnessed to enhance immunotherapies. CRISPR-modified T cells, including CAR-T cells, have been engineered for improved tumor targeting, resistance to immunosuppressive microenvironments, and reduced off-target toxicity. CRISPR-Cas9 screens in hematological malignancies have uncovered novel oncogenic drivers, resistance mechanisms, and potential drug targets, guiding precision oncology strategies (74). Base and prime editors are additionally being explored to correct oncogenic point mutations in tumor suppressor genes or to disrupt driver oncogenes in solid and hematologic tumors (75). The applications of gene editing extend to infectious diseases, where CRISPR-based antiviral strategies enable targeted degradation of viral genomes, including HIV, HBV, HPV, and SARS-CoV-2. These systems can be employed ex vivo in patient-derived cells or potentially in vivo to eliminate viral reservoirs and control chronic infections. Beyond therapeutic interventions, CRISPR diagnostics such as SHERLOCK and DETECTR have emerged as rapid, sensitive tools for pathogen detection, illustrating the dual therapeutic and diagnostic utility of gene editing technologies (76). In regenerative medicine, precise genomic modifications in induced pluripotent stem cells (iPSCs) or tissue-specific progenitors allow the generation of genetically corrected cells for transplantation. CRISPR and base editing facilitate the repair of disease-causing mutations, while prime editing expands the repertoire to small insertions and deletions, enabling the production of patient-specific, mutation-free cellular therapeutics (77). Despite these advances, challenges remain, including efficient delivery of editing machinery, immune responses to Cas proteins, mosaicism in edited tissues, and potential off-target mutations. Viral vectors such as AAV and lentivirus, alongside non-viral methods including lipid nanoparticles and electroporation of ribonucleoprotein complexes, are being optimized to enhance safety and tissue specificity (78). Moreover, ethical considerations, regulatory hurdles, and long-term safety monitoring are crucial for responsible clinical deployment.

Figure 6. Applications of gene editing technologies in genetic disorders, illustrating CRISPR-Cas9, base editing, gene repair, and prime editing approaches for the treatment of sickle cell disease, β-thalassemia, muscular dystrophy, and cystic fibrosis.